American Society of Clinical Oncology Annual Meeting: Sarcoma | Conference

The MSK expert explained that pre- and post-test education on genetic testing also improved family discussions about their risk.

A phase II trial showed that the tyrosine kinase inhibitor anlotinib has promising efficacy across a variety of subtypes of advanced refractory soft-tissue sarcoma.

Combined therapy with gemcitabine and pazopanib appears to be a viable treatment option for patients with soft-tissue sarcomas refractory to anthracycline or ifosfamide.